Die Herzgesundheits-App, die endlich die richtige Frage stellt

Es gibt heute Hunderte von Apps für die Herzgesundheit auf dem Markt. Die meisten von ihnen tun dasselbe: Sie überwachen Ihr Herzfrequenz, Ihre Schritte verfolgen, Ihren Schlaf messen und Ihnen sagen, dass Sie mehr Gemüse essen sollen. Einige der ausgefeilteren Geräte lassen sich mit Wearables verbinden und geben Ihnen eine Echtzeit-Messung Ihres Pulses. Einige wenige markieren sogar einen unregelmäßigen Herzschlag.

Das sind nützliche Werkzeuge. Aber sie beantworten alle eine andere Frage.

Herzfrequenzmesser zeigen Ihnen, was Ihr Herz genau in diesem Moment tut. Was sie Ihnen nicht sagen können – was kein Wearable an Ihrem Handgelenk Ihnen sagen kann –, ist, was Ihr Herz in zehn, zwanzig oder dreißig Jahren tun wird, basierend auf dem genetischen Bauplan, den Sie von Ihrer Familie geerbt haben. Diese Frage erfordert eine völlig andere Art von Werkzeug. Und bis jetzt wurde keine App entwickelt, um sie angemessen zu beantworten.

Das ändert sich heute.

Wir präsentieren den Herz-Risiko-Rechner

Das Herz Risikorechner ist jetzt auf Google Play verfügbar und stellt etwas wirklich Neues im Bereich der Herzgesundheits-Apps dar. Es ist kein Herzfrequenzmesser. Es ist kein Schrittzähler. Es ist kein Meditations-Timer oder ein Blutdruck Log. Unserem Wissen nach ist es eine der ersten Verbraucher-Apps, die speziell entwickelt wurde, um das vererbte kardiovaskuläre Risiko mithilfe eines gewichteten Familienanamnese-Rahmens zu quantifizieren – die Vererbter Gefahrenkoeffizient — abgeleitet von Prinzipien, die in begutachteter Fachliteratur veröffentlicht wurden, die in Zirkulation, JAMA, der European Heart Journal, und das Lanzette. ^{[1],[2],[3],[4]}

Die Kernerkenntnis hinter dieser App ist einfach, aber tiefgreifend: dein Familiengeschichte ist keine Ja-oder-Nein-Frage.

Standard-Herzrisikorechner – einschließlich des weit verbreiteten Framingham-Risikoskore Fragen, ob es in Ihrer Familie eine Vorgeschichte von Herzerkrankungen gibt. ^[1] Ja oder nein. Das ist alles. Ein Großelternteil, das stirbt an einem Herzinfarkt mit 82 und einem Geschwisterteil, das zusammenbricht vor plötzlicher Herztod Bei 39 erhalten beide dasselbe Häkchen. Sie sind nicht dasselbe. Nicht einmal annähernd. Und die Forschung ist sich diesbezüglich völlig einig. ^[3],[5]

Was diese App unterscheidet

Es fragt wer, nicht nur ob

Der Herzrisikorechner ordnet die Herzerkrankungen Ihrer Familie nach Verwandtschaftsgrad, Alter beim Auftreten des Ereignisses und Schweregrad des Ausgangs. Ein tödliches Ereignis bei einem Verwandter ersten Grades Ein Ereignis im Alter von 40 Jahren ist mit einem grundlegend anderen genetischen Signal verbunden als ein nicht tödlicher Vorfall bei einem Großelternteil im Alter von 75 Jahren. Die App erfasst diesen Unterschied mathematisch mithilfe eines evidenzbasierten Gewichtungsrahmens, der von Peter Megdal, PhD auf der Grundlage veröffentlichter epidemiologischer Beobachtungen entwickelt wurde:

H = Σ (R × W) / A

Wobei R das Beziehungskoeffizient (0,5 für Eltern und Geschwister, 0,25 für Großeltern sowie Tanten und Onkel), W ist das Schweregradgewichtung des kardiovaskulären Ereignisses, und A ist das Alter, in dem das Ereignis auftrat. Bei der Gleichung handelt es sich um einen evidenzbasierten Bildungsrahmen, der etablierte epidemiologische Risikoprinzipien zu einem strukturierten Score zusammenführt – und so eine strukturierte Schätzung des vererbten familiären Herzk-Risikos liefert, die kein herkömmliches Ankreuzfeld erfassen kann.

Es offenbart das Imaging-Trap

Einer der wichtigsten – und alarmierendsten – Befunde in der jüngeren kardiovaskulären Forschung ist das, was Klinikärzte als die Bildgebungsfalle (Imaging Trap) bezeichnen. Ein standardmäßiger Koronار Arterie Ein Kalzium-Scan, eines der am häufigsten verwendeten Screening-Instrumente in der Kardiologie, kann selbst dann einen Wert von null ergeben, wenn gefährlicher weicher, nicht verkalkte Plaque bildet sich aktiv in Ihren Arterien. ^[6] Für Menschen mit einem signifikanten vererbten kardialen Risiko, ein Null-Kalzium-Score kann bei ausgewählten Patienten eine falsche Sicherheit vortäuschen.

Die randomisierte CAUGHT-CAD-Studie aus dem Jahr 2025 bestätigte, dass bei Patienten mit einer Familienanamnese von vorzeitige koronare Herzkrankheit, Koronare CT-Angiographie kann nicht verkalkte identifizieren Plaque wird durch den Calcium-Score nicht erfasst und kann bei ausgewählten Patienten das therapeutische Vorgehen beeinflussen. ^[7] Der Herz-Risiko-Rechner basiert auf dieser Forschung. Er hilft Ihnen zu verstehen, ob Ihr familiäres Muster Sie zu den Menschen gehören lassen könnte, für die ein zusätzliches Gespräch mit einem Arzt über bildgebende Verfahren sinnvoll sein könnte.

Es erfasst, was Wearables völlig übersehen

Deine Apple Watch kennt deinen Ruhepuls. Sie weiß nicht, dass dein Bruder mit 42 Jahren einen tödlichen Herzinfarkt hatte. Dein Fitbit zeichnet deine Schlafqualität auf. Es kann dir nicht sagen, dass ein Geschwisterteil mit vorzeitiger Herzerkrankung eine Odds Ratio von 2,46 für dein eigenes kardiales Risiko mit sich bringt – eine Zahl, die in von Experten begutachteter Forschung dokumentiert ist, veröffentlicht in JAMA. ^[5] Ihr Garmin misst Ihr VO2 max. Es gibt keine Möglichkeit, die additive vererbte Belastung zu berücksichtigen – was Forscher als Gen-Dosierung bezeichnen –, die auftritt, wenn mehrere enge Verwandte frühzeitig erkranken. Herz-Kreislauf-Erkrankung, was die Wahrscheinlichkeit einer vererbten genetischen Anfälligkeit erheblich erhöht. ^[3],[8]

Wearables messen, was in diesem Moment in Ihrem Körper passiert. Der Herzrisikorechner modelliert das vererbte familiäre Signal, das sich in Ihrer Familienanamnese widerspiegelt, und was dies über Ihre kardiale Entwicklung im Laufe des Lebens aussagt. Wearables und Tools zur Familienanamnese liefern komplementäre, aber unterschiedliche Informationen – doch nur eines davon hilft dabei, Personen zu identifizieren, die von einer intensiveren Untersuchung als dem Standardscreening profitieren könnten.

Das gibt Ihnen etwas, das Sie zu Ihrem Arzt mitnehmen können

Jedes Ergebnis des Herzrisikorechners ist als Gesprächsauftakt formuliert, nicht als Schlussfolgerung. Die App erstellt eine diskussionsbereite Zusammenfassung der Familienanamnese und eine Reihe spezifischer, klinisch fundierter Fragen, die Sie zu Ihrem nächsten Termin mitbringen können. Fragen wie: Könnte ich angesichts meiner familiären Vorbelastung weiche Plaque die ein standardmäßiger Kalzium-Scan übersehen würde? Sollte ich an einen preventive cardiologist rather than managed in primary care? Does my family history change how standard risk tools should be interpreted in my case? ^[9]

These are the questions that can genuinely change the course of a clinical encounter. They are the questions that turn a routine annual physical into a meaningful cardiovascular conversation. And they are the questions that most people never know to ask — because no one has ever organized their family history in a way that makes those questions visible.

It Is Built on Real Science

The Heart Risk Calculator is not a wellness app built on general advice. The concepts incorporated into its framework are informed by more than 40 peer-reviewed publications spanning inherited cardiac risk, premature coronary artery disease, family history epidemiology, und das Genetik of cardiovascular susceptibility. The gene dosing model underlying the Inherited Hazard Coefficient draws on foundational research in inherited cardiovascular disease published in Nature Reviews Cardiology, der Lanzette, und das European Heart Journal. ^[4],[8] The parental and sibling risk data come from landmark studies in JAMA und Zirkulation. ^[3],[5] The clinical significance of early cardiac events in close relatives — and the inadequacy of standard tools in capturing that significance — is documented across decades of cardiovascular epidemiology. ^[9]

This is not an algorithm someone built in a weekend. It is an evidence-informed educational framework, developed as an educational tool by Peter Megdal, PhD, that applies established epidemiologic principles to a problem that standard tools have never been designed to solve.

Why This Matters Right Now

Heart disease remains the number one cause of death in the United States. ^[10] Roughly half of all Americans have a family history of cardiac events. ^[11] And yet the tools available to most people for understanding their inherited risk remain remarkably primitive — a checkbox on an intake form, a Framingham score that was never designed to capture genetic loading, ^[1] and a calcium scan that may miss the most dangerous plaque entirely in younger, gene-dosed individuals. ^[6],[9]

For a 20-year-old whose sibling died of sudden cardiac death at 38, the Framingham Risk Score will often return a ten-year risk of under one percent — because the formula is driven by chronological age, not inherited biology. ^[1] That person’s inherited risk profile may warrant substantially more evaluation than suggested by conventional calculators. And without a tool that models the inherited familial signal in their family history, they will never know to ask the right questions until it is too late.

The Heart Risk app exists for that person. It exists for everyone who has sat in a doctor’s office and said “yes, there’s heart disease in my family” and watched that information disappear into a checkbox that changes nothing about their care.

Download It Today

The Heart Risk Calculator app is available now on Google Play for $4.99. It is an educational tool, not a medical device, and it does not replace clinical evaluation. But it may be the most important five dollars you spend on your heart health — not because it monitors your pulse, but because it finally asks the question that wearables and standard calculators have never been designed to answer.

Your family history is data. It’s time to use it.

This tool is for educational purposes only and does not constitute medical advice. The score has not been prospectively validated for predicting individual cardiovascular events and should not be used to diagnose disease. Always consult a qualified healthcare professional before making health decisions. Research by Peter Megdal, PhD — CuringHeartDisease.com

References

1. D’Agostino RB Sr, Vasan RS, Pencina MJ, et al. General cardiovascular risk profile for use in primary care: the Framingham Heart Study. Circulation. 2008;117(6):743-753. doi:10.1161/CIRCULATIONAHA.107.699579.
2. Virani SS, Alonso A, Aparicio HJ, et al. Heart Disease and Stroke Statistics-2021 Update: A Report From the American Heart Association. Circulation. 2021;143(8):e254-e743. doi:10.1161/CIR.0000000000000950
3. Lloyd-Jones DM, Nam BH, D’Agostino RB Sr, et al. Parental cardiovascular disease as a risk factor for cardiovascular disease in middle-aged adults: a prospective study of parents and offspring. JAMA. 2004;291(18):2204-2211. doi:10.1001/jama.291.18.2204
4. Ference BA, Ginsberg HN, Graham I, et al. Low-density lipoproteins cause atherosclerotic cardiovascular disease. 1. Evidence from genetic, epidemiologic, and clinical studies. A consensus statement from the European Atherosclerosis Society Consensus Panel. Eur Heart J. 2017;38(32):2459-2472. doi:10.1093/eurheartj/ehx144
5. Murabito JM, Pencina MJ, Nam BH, et al. Sibling cardiovascular disease as a risk factor for cardiovascular disease in middle-aged adults. JAMA. 2005;294(24):3117-3123. doi:10.1001/jama.294.24.3117
6. Villines TC, Hulten EA, Shaw LJ, et al. Prevalence and severity of coronary artery disease and adverse events among symptomatic patients with coronary artery calcification scores of zero undergoing coronary computed tomography angiography: results from the CONFIRM (Coronary CT Angiography Evaluation for Clinical Outcomes: An International Multicenter) registry. J Am Coll Cardiol. 2011;58(24):2533-2540. doi:10.1016/j.jacc.2011.10.851
7. Nerlekar N, Vasanthakumar SA, Whitmore K, et al. Effects of Combining Coronary Calcium Score With Treatment on Plaque Progression in Familial Coronary Artery Disease: A Randomized Clinical Trial. JAMA. 2025;333(16):1403-1412. doi:10.1001/jama.2025.0584
8. Bachmann JM, Willis BL, Ayers CR, Khera A, Berry JD. Association between family history and coronary heart disease death across long-term follow-up in men: the Cooper Center Longitudinal Study. Circulation. 2012;125(25):3092-3098. doi:10.1161/CIRCULATIONAHA.111.065490
9. Arnett DK, Blumenthal RS, Albert MA, et al. 2019 ACC/AHA Guideline on the Primary Prevention of Cardiovascular Disease: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines. Circulation. 2019;140(11):e596-e646. doi:10.1161/CIR.0000000000000678
10. Martin SS, Aday AW, Allen NB, et al. 2025 Heart Disease and Stroke Statistics: A Report of US and Global Data From the American Heart Association. Circulation. 2025;151(8):e41-e660. doi:10.1161/CIR.0000000000001303
11. Moonesinghe R, Yang Q, Zhang Z, Khoury MJ. Prevalence and Cardiovascular Health Impact of Family History of Premature Heart Disease in the United States: Analysis of the National Health and Nutrition Examination Survey, 2007-2014. J Am Heart Assoc. 2019;8(14):e012364. doi:10.1161/JAHA.119.012364

---

Addendum

Evidentiary Basis for the Inherited Hazard Coefficient Algorithm

Companion document to: “The Heart Health App That Finally Asks the Right Question”

Overview

The Inherited Hazard Coefficient (IHC) is computed using the formula:

H = Σ (R × W) / A

Where R is the relation coefficient (0.5 for first-degree relatives: parents and siblings; 0.25 for second-degree relatives: grandparents, aunts, and uncles), W is the severity weight of the cardiac event, A is the age at which the event occurred, and Σ represents summation across all affected relatives in the family history.

Each structural element of this formula — the relation coefficient R, the severity weight W, the age denominator A, and the summation logic — is grounded in a specific body of peer-reviewed cardiovascular epidemiology. This addendum identifies the primary literature supporting each component and distinguishes that evidence from the design choices that represent the author’s own evidence-informed synthesis.

The R Term: Relation Coefficient

The R term encodes the degree of biological relatedness between the patient and the affected family member. First-degree relatives (parents, siblings) receive a coefficient of 0.5, reflecting the 50% shared genome. Second-degree relatives (grandparents, aunts, uncles) receive 0.25, reflecting 25% shared genome. The differential weighting of first- versus second-degree relatives is supported by two landmark Framingham-based studies.

Lloyd-Jones et al., JAMA 2004

^[1] This prospective Framingham offspring analysis was among the first to rigorously confirm parental cardiovascular disease as an independent predictor of offspring CVD after full adjustment for conventional Risikofaktoren. Critically, the study demonstrated that risk compounded when both parents were affected — the conceptual foundation for the summation structure of the IHC. The paper directly supports the assignment of the 0.5 coefficient to parents and the differential weighting of first-degree versus second-degree relatives.

Murabito et al., JAMA 2005

^[2] This companion Framingham sibling analysis documented an unadjusted odds ratio of 2.46 for cardiovascular disease in individuals with an affected sibling — a magnitude comparable to or exceeding that of parental history in certain subgroups. This finding is the primary justification for assigning siblings the same R coefficient of 0.5 as parents, rather than a lower value. It also reinforced the core principle that first-degree relatives constitute a categorically different risk tier from second-degree relatives.

The A Term: Age at Event in the Denominator

The A term places the age at which the family member experienced their cardiac event in the denominator of the formula, so that younger events produce a higher IHC contribution. This is the most clinically consequential structural feature of the algorithm and is supported by consistent findings across multiple data sources.

Lloyd-Jones et al., JAMA 2004 and Murabito et al., JAMA 2005

^[1],[2] Both Framingham analyses stratified their findings by age at the family event and demonstrated substantially elevated risk when the cardiac event was premature — defined as occurring before age 55 in male relatives and before age 65 in female relatives. A family event at age 40 carries a fundamentally different inherited signal than the same event at age 78. The A term in the denominator is a direct mathematical encoding of this well-established epidemiologic principle.

D’Agostino et al., Circulation 2008 — Framingham Risk Score

^[3] Cited in the main article as the primary example of a risk calculator that does nicht account for age at the family event. The Framingham score uses the patient’s own chronological age as its dominant driver of 10-year risk, but incorporates no variable for the age at which family members experienced cardiac events. The A denominator in the IHC formula is specifically designed to correct for this gap — capturing what the Framingham score systematically omits.

The W Term: Severity Weight

The W term assigns differential weights to cardiac events based on their severity — with fatal events, sudden cardiac death, and early revascularization receiving higher weights than medically managed non-fatal events. This reflects the well-documented relationship between event severity and underlying atherosclerotic burden.

Villines et al., JACC 2011 — CONFIRM Registry

^[4] This large multicenter CCTA registry demonstrated that even among patients with a CAC score of zero — conventionally considered low risk — a meaningful proportion harbored non-calcified, potentially obstructive plaque. The study provided strong evidence that event severity and plaque characteristics are not uniform across patients with nominally similar risk profiles. Fatal events in first-degree relatives imply a higher inherited plaque burden and more aggressive disease trajectory than non-fatal, medically managed events — the epidemiologic rationale for the W severity weighting.

Nerlekar et al., JAMA 2025 — CAUGHT-CAD Trial

^[5] This 2025 randomized trial in patients with a family history of premature CAD demonstrated that non-calcified plaque burden varied substantially even among individuals within the same broad family history category. The trial used CCTA to quantify plaque progression as its primary endpoint, confirming that severity differentiation within the inherited risk spectrum has measurable clinical significance — and is not captured by binary family history classification or calcium scoring alone.

The Σ Term: Summation Across Relatives

The summation operator reflects the principle that inherited cardiac risk compounds with each additional affected relative. A patient with two affected first-degree relatives carries a meaningfully different inherited signal than a patient with one. The Σ structure encodes this dose-response relationship mathematically.

Bachmann et al., Circulation 2012 — Cooper Center Longitudinal Study

^[6] This large prospective study of men followed over decades demonstrated that family history of coronary heart disease death was associated with significantly elevated long-term cardiovascular mortality, and that the risk accumulated across the follow-up period in a manner consistent with an underlying dose-response relationship. The study supports the logic of summing contributions across affected relatives rather than treating family history as a single binary flag.

Ference et al., European Heart Journal 2017

^[7] This Mendelsche Randomisierung analysis demonstrated that the atherogenic effect of LDL-Cholesterin — the primary driver of inherited lipid-related cardiac risk — is cumulative and time-dependent. Lifetime exposure to elevated LDL produces atherosclerotic burden that is proportional to the integral of exposure over time, not simply to any single measurement. This biological framework supports the IHC summation structure: inherited cardiovascular risk is not a point estimate but a cumulative signal that should be aggregated across all affected relatives and weighted by the severity and timing of their events.

What the Literature Validates — and What It Does Not

What is validated

The peer-reviewed literature cited above establishes the following with high confidence:

• First-degree relatives confer greater inherited cardiac risk than second-degree relatives.
• Siblings carry risk comparable to parents, not intermediate between parents and grandparents.
• The age at which a family member experienced a cardiac event is a critical variable: premature events confer dramatically greater inherited signal than late-life events.
• Multiple affected relatives compound inherited risk in a dose-response fashion.
• Event severity correlates with underlying atherosclerotic burden and is not uniform across family history reports.
• Standard risk calculators systematically underutilize this information, particularly in younger patients with strong family histories.

What is not validated

The existing literature does nicht validate:

• The specific coefficient values chosen for R (0.5 and 0.25).
• The specific severity weight values assigned to W.
• The mathematical form of dividing by A rather than applying a categorical age-at-event modifier.
• The formula H = Σ(R×W)/A as a clinically calibrated predictive score for individual cardiovascular event risk.
• The IHC against any prospective outcome dataset.

The IHC formula is an evidence-informed educational framework that translates established epidemiologic principles into a structured, quantitative estimate of inherited familial cardiac risk. The inputs are grounded in landmark peer-reviewed literature. The specific mathematical implementation — the coefficient values, the weighting scheme, and the formula structure — represents the author’s synthesis of those principles and has not been independently validated. The ACC/AHA Primary Prevention Guideline ^[8] explicitly recognizes family history as a risk-enhancing factor that should modify clinical decision-making, but stops short of providing a quantitative formula for doing so. The IHC is designed to fill precisely that gap.

References

1. Lloyd-Jones DM, Nam BH, D’Agostino RB Sr, et al. Parental cardiovascular disease as a risk factor for cardiovascular disease in middle-aged adults: a prospective study of parents and offspring. JAMA. 2004;291(18):2204-2211. doi:10.1001/jama.291.18.2204
2. Murabito JM, Pencina MJ, Nam BH, et al. Sibling cardiovascular disease as a risk factor for cardiovascular disease in middle-aged adults. JAMA. 2005;294(24):3117-3123. doi:10.1001/jama.294.24.3117
3. D’Agostino RB Sr, Vasan RS, Pencina MJ, et al. General cardiovascular risk profile for use in primary care: the Framingham Heart Study. Circulation. 2008;117(6):743-753. doi:10.1161/CIRCULATIONAHA.107.699579
4. Villines TC, Hulten EA, Shaw LJ, et al. Prevalence and severity of coronary artery disease and adverse events among symptomatic patients with coronary artery calcification scores of zero undergoing coronary computed tomography angiography: results from the CONFIRM (Coronary CT Angiography Evaluation for Clinical Outcomes: An International Multicenter) registry. J Am Coll Cardiol. 2011;58(24):2533-2540. doi:10.1016/j.jacc.2011.10.851
5. Nerlekar N, Vasanthakumar SA, Whitmore K, et al. Effects of Combining Coronary Calcium Score With Treatment on Plaque Progression in Familial Coronary Artery Disease: A Randomized Clinical Trial. JAMA. 2025;333(16):1403-1412. doi:10.1001/jama.2025.0584
6. Bachmann JM, Willis BL, Ayers CR, Khera A, Berry JD. Association between family history and coronary heart disease death across long-term follow-up in men: the Cooper Center Longitudinal Study. Circulation. 2012;125(25):3092-3098. doi:10.1161/CIRCULATIONAHA.111.065490
7. Ference BA, Ginsberg HN, Graham I, et al. Low-density lipoproteins cause atherosclerotic cardiovascular disease. 1. Evidence from genetic, epidemiologic, and clinical studies. A consensus statement from the European Atherosclerosis Society Consensus Panel. Eur Heart J. 2017;38(32):2459-2472. doi:10.1093/eurheartj/ehx144
8. Arnett DK, Blumenthal RS, Albert MA, et al. 2019 ACC/AHA Guideline on the Primary Prevention of Cardiovascular Disease: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines. Circulation. 2019;140(11):e596-e646. doi:10.1161/CIR.0000000000000678